Excelsior Biopharma Inc. (TPEX:6496)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
25.90
-0.30 (-1.15%)
Mar 10, 2026, 9:56 AM CST
-14.10%
Market Cap 1.22B
Revenue (ttm) 898.26M
Net Income (ttm) -183.17M
Shares Out 46.75M
EPS (ttm) -3.97
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 28,234
Average Volume 19,415
Open 26.20
Previous Close 26.20
Day's Range 25.50 - 26.20
52-Week Range 21.55 - 30.55
Beta -0.06
RSI 39.75
Earnings Date Feb 11, 2026

About Excelsior Biopharma

Excelsior Biopharma Inc. develops and sells pharmaceutical products in Taiwan, China, and internationally. It offers general pharmaceuticals; orphan drugs; antidotes; rapid test kits and reagent; consumer products under the Repavar, Om3gafort, Oral7, and Excelsior Probiotics brand names; and over the counter drugs under the Norit, Puresenna, and Tazac brand names. The company also provides specialty medicine and public health products. In addition, it is involved in importing and exporting of active pharmaceutical ingredients, food, and cosmece... [Read more]

Sector Healthcare
Founded 1986
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 6496
Full Company Profile

Financial Performance

In 2025, Excelsior Biopharma's revenue was 898.26 million, an increase of 4.22% compared to the previous year's 861.91 million. Losses were -183.17 million, 85.6% more than in 2024.

Financial Statements

News

There is no news available yet.